SG11202111192TA - Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies - Google Patents

Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies

Info

Publication number
SG11202111192TA
SG11202111192TA SG11202111192TA SG11202111192TA SG11202111192TA SG 11202111192T A SG11202111192T A SG 11202111192TA SG 11202111192T A SG11202111192T A SG 11202111192TA SG 11202111192T A SG11202111192T A SG 11202111192TA SG 11202111192T A SG11202111192T A SG 11202111192TA
Authority
SG
Singapore
Prior art keywords
diabodies
bispecific
cds
treatment
dosing regimens
Prior art date
Application number
SG11202111192TA
Inventor
Jan Davidson
Ian Lent
Krishnan Sampathkumar
Ralph Alderson
Motte-Mohs Ross La
Jon Wigginton
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of SG11202111192TA publication Critical patent/SG11202111192TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SG11202111192TA 2019-04-10 2020-04-08 Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies SG11202111192TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962831969P 2019-04-10 2019-04-10
US201962831979P 2019-04-10 2019-04-10
US201962929401P 2019-11-01 2019-11-01
US201962929381P 2019-11-01 2019-11-01
US202063001388P 2020-03-29 2020-03-29
PCT/US2020/027140 WO2020210277A1 (en) 2019-04-10 2020-04-08 Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies

Publications (1)

Publication Number Publication Date
SG11202111192TA true SG11202111192TA (en) 2021-11-29

Family

ID=72751774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111192TA SG11202111192TA (en) 2019-04-10 2020-04-08 Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies

Country Status (13)

Country Link
US (1) US20220213203A1 (en)
EP (1) EP3953391A1 (en)
JP (1) JP2022526640A (en)
KR (1) KR20210149807A (en)
CN (1) CN113728009A (en)
AU (1) AU2020272734A1 (en)
BR (1) BR112021020265A2 (en)
CA (1) CA3136255A1 (en)
IL (1) IL287095A (en)
MX (1) MX2021012263A (en)
SG (1) SG11202111192TA (en)
TW (1) TW202104263A (en)
WO (1) WO2020210277A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022276523A1 (en) * 2021-05-21 2024-01-18 Aptevo Research And Development Llc Dosing regimens for protein therapeutics
JP2024530465A (en) * 2021-08-06 2024-08-21 ウニバズィテート バーゼル Identifiable cell surface protein variants for use in cell therapy - Patents.com

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. Dosing regimens of bi-specific cd123 x cd3 diabodies in the treatment of hematologic malignancies

Also Published As

Publication number Publication date
CA3136255A1 (en) 2020-10-15
TW202104263A (en) 2021-02-01
IL287095A (en) 2021-12-01
AU2020272734A1 (en) 2021-11-18
JP2022526640A (en) 2022-05-25
BR112021020265A2 (en) 2022-01-11
WO2020210277A1 (en) 2020-10-15
CN113728009A (en) 2021-11-30
US20220213203A1 (en) 2022-07-07
EP3953391A1 (en) 2022-02-16
KR20210149807A (en) 2021-12-09
MX2021012263A (en) 2022-01-06

Similar Documents

Publication Publication Date Title
IL266496A (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL266424B1 (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
HK1249854A1 (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
IL279251A (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
MA44145A (en) BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
IL276303A (en) Methods for treating cancer with anti-pd-1 antibodies
IL278057A (en) Systems and methods for modifying adaptive dosing regimens
IL282663A (en) Bt1718 for use in treating cancer
IL272088A (en) Dhodh inhibitor for use in treating hematologic cancers
MX2018000267A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer.
IL287095A (en) Dosing regimens of bispecific cd123 x cd3 diabodies in the treatment of hematologic malignancies
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
SG10201912545PA (en) T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
IL279005A (en) Anti-cd37 immunoconjugate dosing regimens
IL278889A (en) Dosing regimen for the treatment of pi3k related disorders
IL279764A (en) Abrasive articles and methods for forming same
IL288086A (en) Methods and materials for treating cancer
IL259271B (en) Treatment regimens for hematologic cancers and methods of use thereof
IL276358A (en) Compounds and methods for treating addiction and related disorders
IL288010A (en) Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies
IL265762A (en) Dosing regimen of avelumab for the treatment of cancer
IL279756A (en) Abrasive articles and methods for forming same
IL273909A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab